Intravenous epoprostenol for treatment-refractory reversible cerebral vasoconstriction syndrome (RCVS)
详细信息 查看全文
- 作者：Anya L. Thydé ; na ; b ; anya.l.thyden@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Ali A. Muhamadc ; ali.muhamad@regionh.dk" class="auth_mail" title="E-mail the corresponding author ; Anne Jacobsend ; anne.jacobsen.01@regionh.dk" class="auth_mail" title="E-mail the corresponding author ; Daniel Kondziellaa ; daniel.kondziella@regionh.dk" class="auth_mail" title="E-mail the corresponding author
- 关键词：Epoprostenol ; Prostaglandins ; Nimodipine ; Reversible cerebral vasoconstriction syndrome ; Intracranial vasospasm ; Thunderclap headache ; Cerebral infarction ; Cerebral hemorrhage
- 刊名：Journal of the Neurological Sciences
- 出版年：2016
- 出版时间：15 May 2016
- 年：2016
- 卷：364
- 期：Complete
- 页码：56-58
- 全文大小：366 K
文摘
- •
Treatment of RCVS usually involves nimodipine, but scientific evidence is lacking.
- •
RCVS refractory to nimodipine treatment may be fatal.
- •
Intravenous epoprostenol may decrease the degree of vasoconstriction.
- •
Two patients with treatment refractory RCVS received i.v. epoprostenol.
- •
One patient had a good clinical outcome.